Silexion Therapeutics Initiates $6 Million Public Offering
In a recent development, Silexion Therapeutics Corp. (NASDAQ: SLXN), a company at the forefront of biotechnology, has announced a public offering aimed at raising $6 million. This offering includes 1,500,000 ordinary shares at a price of $4.00 per share, along with series A and series B warrants.
Details of the Offering
Each ordinary share will come with a warrant, allowing investors to purchase additional shares at the same price of $4.00. The series A warrants can be exercised immediately and will expire within five years, while series B warrants are effective for a shorter duration of one year. The offering is anticipated to close shortly, contingent upon customary conditions being fulfilled.
Role of Placement Agent
H.C. Wainwright & Co. has been appointed as the exclusive placement agent for this offering. Their expertise will be essential in facilitating and overseeing the execution of the transaction.
Use of Proceeds
The gross proceeds from this offering, which amount to $6 million before expenses, are earmarked for increasing investment in pre-clinical studies and enhancing general corporate activities. This infusion of capital underscores Silexion's commitment to advancing its innovative therapies for treating cancer.
Regulatory Compliance
This public offering aligns with the regulatory framework established by the Securities and Exchange Commission (SEC). It follows a registration statement on Form S-1 that has been recently approved, ensuring all necessary legal considerations are met.
About Silexion Therapeutics
Silexion Therapeutics is a trailblazer in the clinical-stage biotech sector, focusing specifically on developing groundbreaking treatments for solid tumors associated with the mutated KRAS oncogene. This gene is recognized as a significant driver in various human cancers. The company has successfully conducted a Phase 2a clinical trial, revealing promising results that suggest its first-generation product has potential advantages over traditional chemotherapy.
Commitment to Oncology
With a heart for advancing oncology treatments, Silexion is passionate about providing new options for patients suffering from KRAS-driven cancers. The company's ambition is to further develop its lead product candidate aimed at locally advanced pancreatic cancer, a condition with limited treatment options.
Contact Information
For further details about the offering or Silexion's initiatives, individuals can reach out directly to the company. The main contact is Ms. Mirit Horenshtein Hadar, CFO, via email at mirit@silexion.com.
For investment inquiries, the Capital Markets Advisors at ARX can be contacted at silexion@arxadvisory.com.
Frequently Asked Questions
What is the purpose of Silexion's public offering?
The public offering aims to raise funds for advancing pre-clinical studies and supporting general corporate purposes.
How much capital is Silexion hoping to raise?
Silexion is attempting to raise a total of $6 million through this public offering.
Who is managing the offering?
H.C. Wainwright & Co. is the exclusive placement agent for this offering.
What are the key components of the securities being offered?
The offering includes ordinary shares and warrants, allowing for additional shares to be purchased at a price of $4.00 per share.
What oncology treatments is Silexion focusing on?
Silexion is dedicated to developing treatments for solid tumors associated with the mutated KRAS oncogene.
